

Press Release

Daiichi Sankyo Establishes New Subsidiaries in Mexico and Colombia

Tokyo, Japan - (August 21, 2024) –Daiichi Sankyo (TSE: 4568) today announced that it has established new subsidiaries in Mexico and Colombia. With the establishment of these two subsidiaries, there are now 32 countries and regions in which the Daiichi Sankyo group of companies is present.

In addition to Brazil, Daiichi Sankyo will contribute to healthcare for more than 60% of the total population of 640 million in Latin America with the addition of these two new affiliates, further strengthening the foundation of our global innovative business expansion by focusing on oncology products.

[Outline of new affiliates]

Country	Mexico	Colombia
Name	Daiichi Sankyo Mexico, Sociedad Anonima de Capital Variable	Daiichi Sankyo Colombia, Sociedad por Acciones Simplificadas
Capital Structure	49,999 stocks owned by Daiichi Sankyo Co., Ltd., 1 stock owned by Daiichi Sankyo Business Associe*	Wholly owned by Daiichi Sankyo (100%)
Date of Establishment	August 2, 2024	June 27, 2024
Description of business	Development, sales and marketing of pharmaceutical products	

* Per the local Company Act, there must be at least two owners.

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

Media Contacts:

Global/Japan:
Daiichi Sankyo Co., Ltd.
DS-PR@daiichisankyo.co.jp

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp